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Intracranial aneurysms are a common vascular abnormality identified incidentally 
or after rupture leading to aneurysmal subarachnoid hemorrhage. However, accurately 
assessing the risk of aneurysmal disease progression is challenging. Here we propose 
a prospective cohort study to identify if elevated levels of matrix metalloproteinase-9, a 
molecular marker of vascular degeneration, in the peripheral blood samples of subjects 
with unruptured intracranial aneurysms correlate with aneurysm progression over a 
follow up period. This study aims to aid in identifying patients at increased risk of 
aneurysm progression in order to guide treatment decisions and ultimately decrease 










CHAPTER 1 - INTRODUCTION 
1.1 - Overview of Aneurysmal Epidemiology, Significance, and Detection 
Intracranial aneurysms (IAs) are acquired pathological expansions of the 
intracranial vasculature often presenting in adulthood as nontraumatic or aneurysmal 
subarachnoid hemorrhage (aSAH) secondary to aneurysmal rupture. It is estimated that 
between 3% and 6% of the United States population over the age of 30 harbors an IA 
with this incidence increasing with age.1, 2, 3, 4, 5, 6 One quarter of these individuals have 
multiple IAs.7 Several IA subtypes exist based on their morphology to include saccular, 
fusiform, and dissecting forms.8 Between 80%-90% of all IAs are saccular, also known 
as berry aneurysms, due to their rounded appearance.7 Saccular IAs are characterized 
by their thin or absent tunica media and internal elastic lamina and are found largely at 
arterial bifurcations near the circle of Willis at the base of the brain.9,10,11 
aSAH secondary to rupture poses the most serious health effect of IAs, occurring 
with an estimated incidence of 30,000 per year in North America.12 While most IAs do 
not progress to rupture, rupture carries with it a significant health burden. Despite 
advances in treatment, fatality is approximately 45% one month after rupture.13 Greater 
than 40% of aSAH survivors never return to pre-morbid capabilities.14 Of these, 10% - 
20% are unable to function independently.15 Identification of IAs prior to rupture is thus 
important, considering the high morbidity and mortality associated with aSAH.  
IA detection is performed using magnetic resonance angiography (MRA), 
computed tomographic angiography (CTA), or invasive angiography. Despite the large 
number of people harboring IAs, approximately 50% of these aneurysms are found only 
after rupture.16 Of the remaining 50% of IAs found prior to aSAH, small IAs measuring < 
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7mm are often asymptomatic and thus found incidentally. Larger IAs, accounting for 
15% of all IAs, are more likely to cause symptoms leading to identification such as 
headaches, seizures, motor or sensory changes, or third nerve palsy.17 
Screening via CTA or MRA is recommended in patients seen to be at increased 
risk of IA formation or rupture such as those with ≥2 family members with IA or SAH, 
conditions such as Polycystic Kidney Disease, Marfan’s syndrome, type IV Ehlers-
Danlos syndrome, neurofibromatosis type 1, alpha-1-antitrypsin deficiency, 
fibromuscular dysplasia, pheochromocytoma, and Klinefelter's syndrome, as well as 
congenital malformations such as coarctation of the aorta, bicuspid aortic valve, and 
intracranial arteriovenous malformations, as these patients generally follow a distinctly 
different treatment course and present at earlier ages.18 
 
1.2: Treatment Options and Associated Risks 
Treatment of identified IAs is accomplished in one of two ways, either via surgical 
intervention or observation. Both carry health risks as intervention carries the risk of 
invasive complications while observation places the patient at risk of aSAH. 
Surgical treatment is generally accomplished either by open craniotomy with 
vascular clipping or endovascular coil embolization. Both surgical treatments are 
associated with non-trivial chances of complications. One large prospective cohort 
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demonstrated that clipping was associated with a severe functional disability of 17.5% 
at 30 days post-op and a 2.3% chance of death at post-op day 30.19 These percentages 
increase in patients older than 50 years old.18, 20 Craniotomy with clipping, as a more 
invasive treatment than endovascular coiling, is associated with more disability 
immediately after the procedure, most of which resolve over time.21 Despite this, one 
large review reported a 13.7% chance of morbidity in clipping vs a 4.0% associated with 
coiling, with risk increasing with age. As such Endovascular coiling is generally seen as 
safer and is performed more commonly.20 However, coiling is still associated with 
thromboembolic events, intraoperative IA rupture, and a greater need for re-intervention 
due to coil compaction.21 
 
1.3 - Risk of Disease Progression 
One of the main challenges in IA management is determining which IAs are at an 
increased risk of rupture and thus require intervention. IAs have a 0.95% risk of rupture 
per year according to a large prospective cohort of Japanese descent.22 This risk has 
been found to be as high as 1.4% per year in a recent systematic review.23 Physically, 
rupture is dependent on the interaction between wall tension versus wall strength as 
described by Laplace’s Law which states that vascular wall tension increases as a 
function of vessel size, intravascular pressure, and wall thinness.7, 24, 25, 26 The risk of 
SAH associated with IA rupture has thus historically been understood as a function of IA 
size, where larger IAs are more prone to rupture.22, 27 Multiple studies have 
demonstrated higher overall risk for IA rupture in IAs >7mm.7, 22, 28 However, size alone 
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is insufficient to accurately assess IA rupture risk as it is common for IAs under 7mm to 
rupture.29 A more detailed discussion of IA rupture covariates is included in Chapter 2.  
 
1.4 - Treatment Guidelines 
Treatment decisions regarding IAs require careful weighing of the risk of rupture 
against the risk of surgical complications in the setting of age.7 However, guidelines rely 
on expert opinion in the context of IA natural history. Nevertheless, these guidelines 
recommend that surgical treatment be advocated in patients with symptomatic or large 
IAs, especially in younger patients or IAs in the posterior circulation, as the risk of 
rupture is seen to outweigh the risks of intervention.19, 27, 30, 31, 32 Because risk of aSAH 
increases with IA size while risk of surgical complications increases with age, guidelines 
recommend that surgical treatment is appropriate in patients under 60 with IAs > 7mm, 
preferably via endovascular coiling to reduce complication risks.19 In patients over 60, 
intervention is usually recommended in IAs >12mm. 
Conservative management via observation is advocated in asymptomatic IAs 
<7mm, and is composed of serial imaging with aggressive control of modifiable risk 
factors for aSAH such as reduction in smoking ,alcohol, and blood pressure.5 The 
American Heart Association suggests that a follow up image at 6-12 months after 
discovery followed by a 12-24 month follow up image is reasonable.18 Other sources 
recommend reimaging of small aneurysms every six months as they may be at higher 
risk of progression.7 IAs measuring 7-10mm need to take into account the patient's age 
and comorbidities.33 Despite these guidelines, conservative management retains a risk 
of sudden IA rupture. Further, assessment for IA growth requires expensive imaging 
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tests, highlighting the need for timely and cost-effective alternatives to assess for 
disease progression. Understanding the role inflammation plays in the disease 
progression may aid in these tasks. 
 
1.5 - Aneurysmal Histology and Development 
Arterial walls are composed of 3 layers from innermost to outermost. The 
innermost layer, the tunica intima, is composed of an endothelial cell layer, a 
subendothelium composed of the extracellular matrix proteins collagen, elastin, and 
ground substance. The internal elastic lamina composed of collagens and elastins.34 
The Tunica media is composed of vascular smooth muscle cells (VSMCs) and the 
external elastic lamina composed of elastin and collagen fibers. Elastin fibers stretch 
while collagen fibers provide rigid support with little ability to stretch prior to failure. The 
outermost layer is the tunica externa composed of collagen fibers, fibroblasts, and the 
vasa vasorum. Additionally, while the tunica media contains an external elastic lamina in 
most arteries throughout the body, the cerebral vasculature does not contain this 
additional elastic layer.34 The lack of an external elastic lamina in cerebral arteries lends 
them more prone to aneurysm formation as the elastic lamina and collagen fibers 
provide resistance to stretch related deformation and structural strength respectively.24, 
35 
Histological examinations of IA reveal several pathological changes in these 
three arterial layers.36 The most widely observed is the loss of the internal elastic lamina 
and atrophy of the tunica media is considered a hallmark of the disease and forces the 
remaining collagen fibers of the tunica externa to maintain the bulk of aneurysmal 
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structural integrity.3, 9, 24, 36, 37 These findings are often found in the presence of fibrotic 
changes and infiltration of leukocytes into the remaining arterial wall. Leukocytes within 
IA walls secrete inflammatory chemoattractants and enzymes such as matrix 
metalloproteinases (MMPs)which are known to degrade the arterial wall components.38, 
39 
These histological changes are caused by pathologic blood flow near arterial 
bifurcations which expose vascular endothelial cells to two increased wall stresses.40 
The first is cyclic transmural stress caused by arterial pulsations related to blood 
pressure, the other is wall shear stress, a frictional force generated as blood flows past 
the arterial wall through the vessel lumen. Increases in either, through hypertension or 
via non laminar flow at arterial bifurcations and curvatures, is noxious to endothelial 
cells and causes the release of inflammatory adhesion molecules, reactive oxygen 
species, and complement system activation.3, 7, 39 This endothelial damage and its 
resulting inflammatory response begins a process of vascular remodeling.8   
The remodeling process requires a balance between cell proliferation, cell 
apoptosis, and extracellular matrix reconstruction via a variety of factors, enzymes, and 
second messengers.39, 41, 42 In IA development, tissue breakdown outpaces tissue 
construction as leukocyte infiltration leads to VSMC apoptosis and progressive tunica 
media thinning.39 Leukocytes secrete proteases such as (MMPs) that act to both 
breakdown extracellular matrix proteins such as collagen and elastin and induce further 
macrophage infiltration.3,24 The degradation of arterial wall layers is believed to be 
catalyzed by these increased MMPs.43 Loss of the internal elastic lamina, ECM, and 
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VSMC layer results in weakening of the vascular wall, allowing for pathologic bulging of 
the IA under arterial pressure. 
 
1.6 - Overview of Matrix Metalloproteinases 
 MMPs are a family of peptidases containing a zinc ion catalytic domain.57 MMPs 
are expressed intra or extracellularly in their inactive form and require activation to 
begin cleavage of their respective substrates.44 Currently there are over 28 individual 
MMPs grouped into six families according to their main substrates although a large 
amount of overlap between families exists.45, 46 Several inhibitors of MMPs, named 
tissue inhibitors of metalloproteinases (TIMPs), also exist. These enzymes and their 
inhibitors are necessary for normal physiological processes such as cell migration, 
wound healing, and tissue remodeling as well as being implicated in many pathogenic 
processes such as cancer metastasis, multiple sclerosis, and aortic disease. Their role 
in IA is believed to be a runaway process of ECM breakdown as collagen and elastin 
are common substrates for several MMPs such as MMP-2, MMP-9, and MMP-12.46 
MMP-9, also known as gelatinase B, is a proteolytic enzyme for collagen types 4, 5, 11, 
and 14, as well as elastin, gelatin, and several other matrix proteins.47 This implicates 
MMP-9 in the degradation of major components of vascular ECM and internal elastic 
lamina, ultimately contributing to IA pathology. 
Circulating plasma levels of MMPs including MMP-9 are increased following both 
IA rupture as well as other forms of stroke. A dose response relationship has been 
described between MMP-9 levels and poor outcome following stroke.48 Additionally, 
other studies have demonstrated increased plasma levels of MMP-9 and decreased 
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levels of its inhibitors in aSAH patients as compared with controls.49 The utility of 
peripheral levels of MMP-9 are further demonstrated as they correlate with NIHSS 
scores following stroke.49 MMP-9 levels have also been demonstrated to predict 
ischemic stroke.50 However, as MMP levels, and MMP-9 in particular, are integral 
components of tissue remodeling, it follows that these enzymes would be increased 
following various events resulting in tissue loss and subsequent remodeling. This paper 
is instead interested in if MMP-9 levels can be used prognostically prior to massive 
tissue damage. A more complete review of MMP-9 in aneurysmal disease is included in 
Chapter 2. 
 
1.7 - Statement of the Problem 
 Intracranial aneurysms are a potentially deadly arterial malformation. However, 
assessment of IA progression is challenging, expensive, and incompletely understood. 
As such there is a need for better disease progression risk stratification in 
conservatively managed patients. MMP-9 activity is implicated in IA pathogenesis and 
progression, but it is unclear if this enzyme can be used prognostically as a biomarker 
for disease progression. 
 
1.8 - Goals and Objectives 
 To establish if elevated MMP-9 concentration in peripheral venous blood 
samples of patients with conservatively managed IAs is associated with IA disease 




1.9 - Hypothesis 
There will be a statistically significantly greater proportion of subjects with IA 
disease progression over the follow-up period among subjects with an unruptured 
intracranial aneurysm (UIA) diagnosed within the last 3 years who are found to have a 
plasma MMP-9 level greater than the 50th percentile among subjects within the study 
group as compared to those with a plasma MMP-9 level less than the 50th percentile 
when controlling for other risk factors. 
 
1.10 – Relevant Definitions 
1) Elevated MMP-9 level is defined as theMMP-9 level being greater than the 50th 
percentile of MMP-9 levels among subjects.  
2) Disease progression is IA growth or identification of aSAH during the study 
period. 
3) Growth is defined as any increase greater than 1 mm in aneurysmal length, 
width, or height upon follow-up CTA or MRA. 
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CHAPTER 2 - REVIEW OF THE LITERATURE 
 
2.1 - Search Criteria 
 We conducted searches of PubMed, Scopus, Ovid, and Cochrane Library 
between January 2021 and April 2021. Searches were conducted using combinations of 
MeSH keywords such as intracranial aneurysm, cerebral aneurysm, brain aneurysm, 
berry aneurysm, saccular aneurysm, mmp-9, gelatinase b, 92-kda gelatinase, matrix 
metalloproteinase, growth, increased size, volume, subarachnoid hemorrhage, SAH, 
bleed, and intracranial hemorrhage. We also examined the references lists of all 
studies. Preference was given to articles published within the last 10 years, however all 
pertinent studies, reviews, and meta-analyses written in or translated to English were 
included. Relevant non-human studies were included due to a relative lack of human 
studies related to the exposure and outcome.  
 
2.2 - Literature Review Introduction 
 
This search demonstrated that MMP-9 presence in the IA wall is a cornerstone of 
IA development and progression as well as significant in post rupture pathology. 
Further, our literature review demonstrates the multifaceted and complex nature, 
highlighting the many covariates at work in this complex disease. Whether plasma 
levels of MMP-9 found in peripheral blood samples are associated with IA progression 
as we have defined it is less clear, mainly due to a relative lack of studies on this 
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subtopic. Widely quoted yet older and smaller studies suggest this is not the case while 
newer studies, at times, suggest the opposite. No studies investigating plasma MMP-9 
levels associated with IA growth were found. 
  
2.3 - Review of MMP-9 in Aortic Aneurysm  
Interest in this topic traditionally stems from studies suggesting that MMPs are 
implicated in aortic aneurysm, which, while not the specific focus of our proposed study, 
deserves brief mention here. A meta-analysis of studies reporting differential protein 
expression in subjects with abdominal aortic aneurysm (AAA) spanning 106 studies 
found that there was a significant increase in circulating MMP-9 levels as compared to 
controls (SMD 0.67 ng/ml; p=0.002; I2 = 91%)1. MMP-9 activity within aortic tissue was 
also increased significantly. Included in this analysis is the 2013 case control study 
consisting of 120 subjects with AAA diagnosed between 1996 and 2007 and 78 controls 
without aneurysmal disease. Plasma samples analyzed via enzyme linked 
immunosorbent assay (ELISA) techniques revealed that MMP-9 levels were higher in 
subjects with AAA vs controls (p<0.05).2 Interestingly, this difference remained 
significant in the analysis of subjects with repaired AAA compared to those without 
repair suggesting that increased MMP-9 levels remain elevated until repair (p<0.05), in 
agreement with other studies3. Further, levels of MMP-9 mRNA demonstrated a 16.3-
fold increase in aortic aneurysmal tissues as compared to the aortic samples of 
controls2. Another study found that elevated plasma levels of MMP-9 had a positive 





2.4 - Review of MMP-9 in IA Animal Models 
Much of the knowledge about MMP-9 in IA, however, stems from animal models 
of the disease. Animal studies have demonstrated MMP-9 plays a significant role in IA 
formation and growth, as well as the protective role of exogenous inhibitors of MMP-9 in 
IA. The important role of MMP-9 in IA progression has been demonstrated in studies 
using MMP analogs such as elastases and collagenases, as well as MMP inhibitors.5, 6 
In one study, IAs were induced in rats via hypertension and injection of elastase.5 
Treatment with doxycycline, a nonselective MMP inhibitor, in doses of 40 mg/kg/day 
reduced IA formation from 70% to 10% (p<0.05) and to 40% in MMP-9 knockout mice 
(p<0.05). Conversely, other animal models demonstrate more severe IA formation via 
MMP disinhibition in TIMP deficient mice relative to control animals.7  
A 2007 paper demonstrates several core features of MMP-9 in the pathogenesis 
of IA using a rat model.8 Investigators induced IAs via high salt diet, left carotid artery 
and bilateral posterior renal artery ligations with resultant hypertensive flow through the 
Circle of Willis according to a standard IA induction protocol. The anterior cerebral 
artery/olfactory artery bifurcation of these animal subjects were then harvested at one 
(n=11) or three months (n=10) post IA induction. MMP-9 tissue levels were then 
assessed using real time polymerase chain reaction (RT-PCR) demonstrating increases 
in MMP-9 at 3 months post induction vs age matched, non-IA induced control subjects 
(p<0.01) expressed as a ratio vs beta actin, a non-MMP sensitive component of arterial 
walls in agreement with many other studies on the topic.9, 10 Further, MMP activity was 
assessed in a separate cohort (n=10) given therapeutic levels (50 mg/kg/day) of 
17 
 
Tolylsam, a nonspecific competitive inhibitor of MMP-2, -9, and -12 vs a control group 
(n=20) after IA induction. 90% of control rats developed both gross (advanced) IA 
bulging and IEL discontinuity, with the remainder developing only discontinuity of the 
IEL. In comparison, 50% of the experimental group developed advanced IAs and IEL 
discontinuity, while the remaining 50% demonstrated only IEL discontinuity. While 
neither the incidence of IA nor the degree of hypertension (control group:160.7±21.1 
mm Hg; n=20; experimental group:161.2±12.2 mm Hg; n=10; p>0.05) were different 
between the two groups, the rate of developing advanced IA changes was significantly 
lower in the experimental group (p=0.013). The number of MMP producing cells within 
the IA wall was also not significantly different between the groups (control 
group:5.4±1.5; n=14; tolylsam group:5.1±1.3; n=10, p>0.05). In situ zymography for 
gelatinase activity was demonstrated in the control rats and not found to be present in 
the treatment group. Overall, this study demonstrates several core features of IA 
disease such as the presence of MMP-9 in IA tissues, the protective role that inhibition 
of MMPs can play, as well as the importance of other risk factors for IA development 
such as hypertension. 
 The role of MMP-9 in the pathogenesis of IAs was further explored in animal 
models demonstrating an increased level of MMP-9 mRNA by RT-PCR in rats with 
induced IAs. 11, 12 In a 2020 paper, investigators attempted to examine the relative 
concentrations of vascular degeneration substances via mRNA level analysis of 36 rats 
with induced IAs relative to sham-operated rats. 11 Significant findings include higher 
MMP-9 mRNA and a higher MMP-9/TIMP-2 mRNA ratio expressed in arbitrary units 
(p<0.01), especially in the posterior cerebral circulation, in the experimental group vs 
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the sham control group. This finding was supported by other studies where investigators 
found that the total number of IAs formed and their rates of rupture were significantly 
increased in rats that underwent IA induction with associated increases in the mRNA 
levels of MMP-9 and MMP-9/TIMP2 ratios (p<0.01) vs sham-operated rats expressed 
as mean and standard deviations in arbitrary units (alpha=0.05; power = 0.8; effect size 
of 0.4). 12 These findings suggest that absolute levels of MMP-9 as well as the relative 
level of activated MMP-9 play important roles in IA formation.   
 While the literature demonstrates that MMPs are strongly implicated in 
aneurysmal pathogenesis and progression, there remains significant ambiguity 
regarding the utility of MMP-9 measurements in blood samples of subjects with IA. 
There are obvious mechanistic components to the relationship of MMP-9 and IA 
disease as described above, however the relationship between MMP-9 and IA 
progression over time requires further investigation. 
 
2.5 - Blood Sampling of MMP-9 in IA Disease 
This literature review found relatively few studies investigating the relationship 
between MMP-9 concentration in the blood of human subjects with IAs and IA disease 
progression despite the mechanistic relationship between them. Indeed, no papers were 
found which assessed for increased size of UIA over a follow up period in relation to 
MMP-9 levels. Instead MMP-9 concentrations were only related to IA presence or 
rupture. Further, the papers that were found often present conflicting or contradictory 
results.  
Our search of the literature found several review articles stating that peripheral 
blood levels of MMP-9 in relation to IA disease would be a fruitless course of 
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investigation. 13, 14, 15 This appears to be largely due to the findings of a single, widely 
quoted paper from 1997 by Kim et al. 9 Here the experimenters attempted to compare 
MMP-9 levels in peripheral plasma samples in human subjects with known IAs (n=6) vs 
those with no known IAs (n=6). The characteristics of each subject such as age, gender, 
IA size, comorbid conditions, etc., are not presented. Results are presented qualitatively 
as approximately the same visual appearance between control and experimental 
samples for the activity of MMP-9 via gelatin zymography. The small sample size, 
ambiguity of both control and IA group characteristics, as well as the qualitative nature 
of result reporting should call into question the validity of this study. Nevertheless, this 
study is widely quoted in the argument against the utility of peripheral blood sampling in 
the assessment of IAs and likely contributed to reduction of interest in the topic of 
assessing peripheral MMP-9 levels in IA disease. 
 The few studies directly measuring peripheral blood levels of MMP-9 following 
Kim’s watershed paper demonstrate a large degree of variability in conclusions. 
However, we have attempted to make it clear that these papers fail to distinguish if the 
increase in MMP-9 found in subjects with RIA causes IA rupture or is caused by IA 
rupture. One such study is a 2018 paper titled “Levels of MMP-9 in patients with 
intracranial aneurysm: Relation with risk factors, size and clinical presentation” by Rojas 
et al. 16 In this case-control study investigators attempt to evaluate the relationship 
between plasma MMP-9 levels and the risk factors that are associated with ruptured 
and unruptured IAs. To do this, peripheral blood samples were taken from 282 subjects 
with IA and 286 age and sex matched control volunteers. Samples were assessed by 
ELISA. In contrast to Kim’s 1997 paper, Rojas et al. thoroughly describe the 
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characteristics of the study participants, including smoking, sex, age, hypertension, 
family history of IAs, IA rupture status, and IA size. The results of the analysis 
demonstrate increased MMP-9 levels, unfortunately expressed as unitless numbers, in 
the patient group as a whole vs control (190.5 +/- 5.4 vs 149.7 +/- 4.7; p<0.0001), the 
ruptured group vs control (p<0.0001) and the unruptured group vs control (p<0.0006). 
Interestingly, no difference in MMP-9 levels were found between RIA and UIA 
(p=0.4792), suggesting that MMP-9 levels do not change significantly post IA rupture, in 
contrast to findings of other papers discussed below. Instead, results suggest MMP-9 
levels can act as an indicator of IA presence regardless of rupture status. Further 
analysis suggests that while MMP-9 levels of subjects with RIAs taken are significantly 
higher than the control group, this difference is significant only in those subjects with 
RIA measuring <12mm (p = 0.008) and >25mm (p = 0.047), with RIA measured 
between 12 and 25 mm having a corresponding p-value of 0.062. This is even more 
true of the UIA group as only the group with UIAs measuring <7mm being statistically 
significant (p = 0.0071). All other UIA size groupings did not correlate with a significant 
difference in MMP-9 levels when compared to controls. This may be due to sub-
optimized sampling methods as evidenced by the fact that only 23 subjects were 
included in the 12-25mm RIA group, and the fact that the UIA group contained only 75 
subjects, 32/75 (42.6%) of those subjects having an IA <7mm.  
 In contrast to these findings, several studies have found significant differences in 
serum MMP-9 concentrations between ruptured and unruptured IAs groups.17, 18 A 2007 
paper titled “Matrix metalloproteinases and tissue inhibitors of metalloproteinases 
expression in human cerebral ruptured and unruptured aneurysm” by Jin et al 
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redemonstrated localized increases of MMP-2 and MMP-9 within IA walls and serum 
samples in subjects with RIAs as compared with UIAs 19. To do this, IA tissue samples 
were collected from 30 patients undergoing IA clipping. These 30 patients were split into 
2 equal groups of 15 each by rupture status (15 RIA, 15 UIA). These samples were 
subsequently analyzed for MMP/TIMP mRNA ratio levels using RT-PCR and compared 
to MMP-2, MMP-9, and TIMP-1,-2,and -3 serum levels using ELISA. Results 
demonstrate that MMP-9 mRNA levels were significantly associated with RIA vs UIA 
(RIA: 5.21 +/- 0.87; UIA: 1.69 +/- 1.00, expressed as a numberless unit relative to the 
enzyme GADPH, p = 0.05). MMP-2 mRNA levels were also significantly higher in the 
RIA group. The serum level branch of this study demonstrated significant (p<0.02) 
increases in MMP-9 and MMP-2 in RIA vs UIA as well (MMP-9: 1066 +/- 43 vs 120 +/- 
27 ng/mL; MMP-2: 1047 +/- 33 vs 110 +/- 26 ng/mL respectively; p<0.02). 
Immunohistostaining demonstrated increased levels of MMP-2, -9, TIMP-1, -2, -3 in the 
RIA group relative to the UIA group as well. Despite these findings, the only conclusion 
that can be reliably drawn is that MMP levels increase after rupture as it is unclear if 
these elevations were the result or cause of rupture. Further loss of utility of the study is 
realized as the study failed to take confounding variables or IA risk factors into account 
in either data presentation or data analysis. As such, the prognostic utility of the study 
cannot be assessed, nor can its conclusions easily inform our own hypothesis.  
Despite these ambiguities and methodological shortcomings, similar conclusions 
were found in a small case-control study evaluating the plasma levels of MMP-9 
assessed via ELISA in human subjects with IA; 3 of which ruptured (mean diameter: 
28mm) and 4 of which did not rupture (mean diameter: 13.5), vs a healthy control 20. 
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Venous plasma levels of MMP-9 were higher in IA subjects as compared to controls 
(p<0.01) as well as higher in subjects with RIA and larger IAs (p<0.05), however exact 
concentrations, means, and standard deviations are not stated. All IA subjects 
underwent surgical clipping which allowed IA samples to be taken and assessed for 
tissue expression of MMP-9. Here results were similar as above, with MMP-9 tissue 
levels assessed via western blot analysis found to be significantly higher in RIAs vs 
UIAs (P<0.01). This study’s use of a control group helps improve its internal validity in 
contrast to Jin, et al. However, its external validity is marred by its small sample sizes 
and poor data reporting.  
 A 2018 paper adds further confusion to the role of MMP-9 in IA disease.21 In this 
paper the investigators carried out a population based case-control study where all adult 
men and women of the city of Malmo, Sweden were invited to undergo baseline 
examinations and peripheral blood draws to assess if various MMP levels would 
correlate with spontaneous SAH over a follow up period from intake spanning 1991-
1996 until SAH, death, emigration away from Sweden, or December 31, 2010, 
whichever occurring first. Baseline examination included BP measurement, BMI, waist 
circumference, smoking and alcohol habits, and current medications taken. Peripheral 
blood samples were drawn and assessed for white blood cell count, MMP-1, -2, -3, -7, -
9, -10, and -12. In total 79 cases with a median time from baseline to SAH of 8.5 years 
(0.4-18.7 years) were compared to 261 controls matched for age and sex. MMP-9 levels 
were found to be higher in cases of SAH as compared with controls, but they failed to 
reach statistical significance in multivariate analysis (adjusted OR 1.06; 96%CI, 0.79-
1.41; p=0.713). Only MMP-7 was significantly associated with an increase in SAH 
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frequency when adjusting for confounders (OR 1.64; 95% CI, 1.19-2.27; p=0.0026). . 
While this study suggests that peripheral sampling of blood to assess for MMP-9 is not 
associated with SAH, it is unclear if the cases in this study included SAH stemming from 
IAs as no imaging of cerebral vasculature was done during subject intake. Indeed, it is 
not clear if vascular imaging was completed at all, or if it was, what proportion of cases 
had undergone this assessment of IA presence as it is not readily clear how diagnosis 
of SAH was identified in the cases. As such, it is not known if the cases had IAs during 
the only assessment of MMP levels during intake or if these cases developed IAs after 
MMP assessment, if at all. As such, this study does not present data directly impacting 
or related to our own when scrutinized to a higher degree.  
 
2.6 - Review of Confounder Variables  
Several variables may affect either MMP-9 activity or IA progression. In general, 
these confounders can be categorized as affecting IA rupture, IA growth, or MMP 
functioning. The following review summarizes the studies most closely related to the 
investigations of these topics.  
 
2.6.1 - Confounding Variables Affecting IA rupture 
Lesion and subject dependent variables related to increased risk of IA 
progression has been a topic of study for many decades. It is generally established that 
IA size, location, shape, and multiplicity play significant roles, as well as subject age, 
sex, ancestry, smoking, SAH history, and hypertension status all contribute to IA 
rupture. Indeed even IA growth itself may predict rupture.22 One large meta-analysis 
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spanning 19 previously published studies and 6556 UIAs followed over 26,122 patient 
years demonstrated that statistically significant risk factors for rupture were age >60 
(RR 2.0; 95% CI, 1.1-3.7), female gender (RR 1.6; 95% CI, 1.1-2.4), Japanese or 
Finnish descent (RR 3.4; 95% CI, 2.6-4.4), IA size >5 mm (RR 2.3; 95% CI, 1.0-5.2), IA 
location in the posterior circulation aneurysm (RR 2.5; 95% CI, 1.6-4.1), and the 
presence of a symptomatic aneurysm (RR 4.4; 95% CI, 2.8-6.8).23 
These findings agree with other large-scale reviews such as the 2014 systematic 
review of 6 prospective studies and 8382 participants with non-traumatic SAH as the 
primary outcome and hazard ratios (HR) representing a 5-year IA rupture risk. This 
study included hypertension as a risk factor, as well as stratified IA size with risk of 
SAH. Specifically, hypertension history or presence (HR 1.4; 95%CI 1.1-1.8) IA size 7-
9.9 mm (HR 2.4; 95%CI 1.6-3.6) IA size 10 mm-19.9 mm (HR 5.7; 95% CI 3.9-8.3) IA 
size >20 mm (HR 21.3; 95% CI 13.5-33.8). If multiple IAs were present in a single 
subject, the largest IA was used in analysis without individual IA analysis. Results are 
comparable to the above reports for IA location in the anterior cerebral arteries (HR1.7; 
95% CI 1.1-2.6), posterior comm artery (HR 2.1; 95% CI 1.4-3.0) posterior arteries (HR 
1.9; 95% CI 1.2-2.9) relative to the Middle cerebral artery (MCA), and subject 
geographic location of Japan (HR 2.8; 95% CI 1.8-4.2) or Finland (HR 3.6; 95% CI 2.0-
6.2) relative to North America when controlling for other covariates using multivariate 
Cox regression analysis.24 While the presence of any prior smoking history was not 
reported in multivariate analysis, this definition appears to be a limited means of 
determining the importance of smoking history, and is in contrast to other studies 
suggesting that smoking increases relative risk of aSAH to as high as 7.3 when 
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controlling for other variables.25 Instead, operationalization via pack-years likely 
represent better methods of determining the importance of smoking on IA rupture. 
Furthermore, familial history of aSAH and aneurysm growth over time were not 
assessed, the latter of which is particularly important to our study. Additionally, 4 of the 
6 studies used in this paper included studies with subjects who underwent clipping or 
coiling of IAs during the follow-up period excluding them from inclusion in risk 
calculations.26, 27, 28, 29 Selection bias found in exclusion of these subjects with a 
potentially higher rupture risk may have skewed results by removing subjects with more 
volatile lesions from data analysis. Furthermore, 6,486 of the 8,382 included subjects 
were of Japanese descent (77.38% of all subjects), highlighting a source of selection 
bias. Indeed, the above meta-analysis includes a widely quoted prospective cohort 
study that followed 5720 adult Japanese subjects with a total of 6697 newly diagnosed 
IAs measuring greater than 3mm.29 Relative to aneurysms that were sized 3 to 4 mm, 
the hazard ratios (HR) for rupture were significantly increased for IA size categories 7 to 
9 mm (HR 3.35; 95% CI, 1.87-6.00; p<0.01), 10 to 24 mm (HR 9.09; 95% CI, 5.25-
15.74; p<0.01), and 25 mm or larger (HR 76.26; 95% CI, 32.76-177.54; p<0.01). HRs 
for IAs 5 to 6 mm were not statistically significant (HR 1.13 (95% CI, 0.58-2.22; p = 
0.71). IAs in the posterior and anterior communicating arteries were more likely to 
rupture as compared to IAs in the middle cerebral artery (HR 1.90; 95% CI, 1.12-3.21; 
p= 0.02; HR 2.02; 95% CI, 1.13-3.58; p = 0.02, respectively). Irregularly shaped IAs 
were also more likely to rupture (HR 1.63; 95% CI, 1.08-2.48; p = 0.02).  
One retrospective cohort study of subjects with UIA demonstrated that risk 
factors for rupture following the multivariate analysis were IA growth (OR 55.9; 95% CI 
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4.47-700.08; p=0.002) and multilobulated IA shape (OR 17.4; 95% CI, 1.52-198.4; 
p=0.022) demonstrated via serial CTA.22 These findings suggest that the limited 
definition of IA progression of either rupture or growth is misleading as a risk factor for 
IA rupture is IA growth. IA growth, therefore, requires its own dedicated discussion. 
 
2.6.2 - Confounding Variables Affecting IA Growth 
Several risk factors of IA growth have been proposed, many of which are the 
same risk factors for IA rupture such as IA size, location, and shape as well as subject 
characteristics such as hypertension, smoking, age, and sex. Of these only IA size, 
shape, multiplicity, and location as well as subject smoking status and hypertension are 
substantiated via meta-analysis. As such, in the absence of MMP exposure designation, 
IA growth is mainly lesion rather than subject specific. For example, one systematic 
review including 4972 UIAs included in 18 studies concluded that irregular IA shape, 
posterior location, IA size greater than or equal to 5mm, and the presence of multiple 
IAs in a single subject were associated with relative risks (RRs) of 2.32 (95% CI, 1.46-
3.68; I2 =91%), 1.94 (95% CI, 1.32-2.38; I2=57%) 2.56 (95% CI, 1.93-3.39; I2 =98%) and 
2.04 (95% CI, 1.56-2.66; I2 =90%) respectively.30 Other parameters such smoking at 
baseline (RR=2.04; 95% CI, 1.56-2.66; I2=90%) and hypertension (RR=2.32; 95% CI, 
1.46-3.68; I2=91%), were statistically significant, though high I2 values may discredit 
these findings somewhat. This review included a retrospective cohort study which found 
that the only risk factor for IA growth measured via serial MRI upon multivariate analysis 
was original IA size >8mm (OR=7.25; 95% CI, 1.96-27.1; P=0.003 ).31 Other variables 
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such as smoking, hypertension, IA multiplicity, and IA location were either not 
statistically significant or not included in multivariate analysis. 
Generally, these agree with the findings reported in a systematic review and 
meta-analysis of IA growth, in which 23 studies and 7208 subjects were included. 
Larger initial aneurysm sizes (OR 2.73; 95%CI, 2.21-3.36; p<0.00001) and smoking 
history (OR 1.45; 95% CI, 1.07-1.98; p = 0.02) were associated with increased odds of 
IA growth.32 Of the studies included in these systematic reviews, one multi-centered 
prospective cohort of 557 non-Japanese subjects followed over a mean of 2.7 years 
assessed risk factors for IA growth as measured via serial CTA or MRA. Multivariate 
analysis via Cox logistic regression showed that size 7 mm-9.9 mm (HR 4.14; 95% CI 
2.04-8.37), 10 mm-19.9 mm (HR8.06, 95% CI 3.89-16.72), >20 mm (HR12.92, 95% CI, 
4.11-40.62) relative to size <7 mm predicted growth rather than rupture during a 5 year 
follow up period.33 Interestingly this study did not find significant increases in hazard 
ratios for IA growth associated with hypertension, age >70, history of previous SAH, or 
IA location. 
 
2.6.3 - Confounding Variables Affecting MMPs 
 While we have taken care to describe confounding variables that may affect the 
primary outcome of our proposed study, time must be taken here to review possible 
confounders of our study’s independent variable, summarized as either exogenous or 
endogenous inhibitors of MMPs. Exogenous inhibitors of MMP-9 include Doxycycline, 
Statins, and Aspirin, all of which are relevant to our study as they are commonly 
prescribed medications for conditions with a high prevalence in the United States. 
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Endogenous inhibitors of MMP-9, such as TIMPs discussed in previous sections, are to 
be considered an intrinsic property of each subject's unique physiology and would 
require their own serological assays and analysis to measure and understand. As such 
they are outside the scope of this study. Therefore, we will restrict the discussion of 
MMP inhibitors here to include only exogenous MMP inhibitors as they are well known 
and feasibly accounted for in our study population. 
 Statins are cited in the literature as effectively lowering the levels or activity of 
MMP-9 in animal models with associated protection against IA progression. Both 
simvastatin and pitavastatin administration are correlated with significant reductions in 
IA size, IEL thickness, MMP mRNA, and macrophage numbers within the IA wall in 
several animal trials. 34, 35. However, a meta-analysis of 10 randomized, placebo 
controlled human trials found no significant change in plasma MMP-9 levels with either 
<12 weeks of statin therapy (SMD: -0.31; 95% CI, -0.81-0.19; p = 0.226) or >12 weeks 
statin therapy (SMD: 0.15; 95% CI, -.91 to 0.60; p = 0.689).36 As such, there is no large 
scale evidence to date that statin use will contribute significant confounding to our 
proposed study. Despite this, we will nonetheless gather information about statin use in 
our study population through intake and outcome assessment forms as these 
medications are commonly prescribed and easily accounted for. 
 Antibiotics of the tetracycline class, specifically doxycycline, have also been 
quoted in the literature as having a protective effect on aneurysmal progression through 
an indirect MMP inhibitory mechanism. 37 One double-blind, placebo controlled trial of 
44 subjects receiving 100mg of doxycycline twice daily for 6 months following AA repair 
vs placebo, matched for multiple characteristics, found that plasma MMP-9 levels were 
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significantly decreased below pretreatment baseline (-11.8% +/- 12.5%; p <0.06) as 
compared to the placebo group (206% +/- 98.5%; p <0.04) with the difference between 
the two groups also being statistically significant (p <0.009).38 This has been 
substantiated in at least one additional AAA study.39 However, a larger randomized 
placebo controlled trial of 286 subjects with AAA found that average AAA growth as 
assessed by ultrasonography was greater in the group receiving 100mg of doxycycline 
daily as compared to the placebo control group over an 18 month period (0.8mm; 95% 
CI. 0.1-1.4 mm; p = 0.016)40 Other studies have found that a daily dose of 150mg of 
doxycycline given over 18 months slows AAA growth compared to placebo (1.5mm 
growth vs 3.0mm growth; p=0.01)41 Generally, however, these studies fail to adjust for 
confounding variables, fail to account for compliance, and/or have small sample sizes, 
all of which call into question the validity of reported findings.42 No studies were found 
examining the effect of doxycycline in human IA disease, nor were any meta-analysis 
found analyzing the body of information on doxycycline in AAA disease. Despite this, 
while doxycycline in the general population is not likely taken over the extended time 
period as found in the above studies, its use in the immediate time before or during our 
study may represent an easily identified source of confounding that should be 
accounted for in our statistical analysis. 
 Lastly, Aspirin has been suggested to be protective against IA progression 
through an MMP-9 inhibitory mechanism.43 Meta-analysis of 5 studies consisting of 
19,222 human subjects found that aspirin administration reduced the risk of non-
traumatic or aSAH (OR 0.51; 95% CI, 0.34-0.76; p = 0.001), though the exact dose and 
frequencies are not reported unambiguously.44 One case-control study used in this 
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analysis compared aspirin use in 4701 subjects with 1,302 (27.7%) cases of aSAH vs 
UIA found that daily dosages of 81 mg of aspirin decreased risk of rupture (OR 0.60; 
95% CI, 0.45-0.80; p <0.05) with a further reduction in rupture risk with increased doses 
to 325 mg daily (OR 0.65; 95% CI, 0.53 -0.81; p<0.01) when adjusting for confounders 
such as age, sex, race, HTN, heart disease, and atrial fibrilation.45 A large case control 
study using ISUIA data to assess the protective role of aspirin use in IA using 58 
subjects with aSAH compared to 213 IA matched controls found that subjects who used 
aspirin at least 3 times weekly had lower odds of IA rupture compared to those who 
never take aspirin upon multivariate analysis using conditional logistic regression.46 
Aspirin use is defined in terms of frequency per week, but no dosages are presented. 
Another large meta-analysis of 10 studies consisting of 1,107,616 subjects reported an 
increase in aSAH only in a subgroup that used aspirin for less than 3 months (OR 
1.697; 95% CI, 1.175-2.452; p = 0.005).47 Despite this, the available data supports the 
notion that aspirin administration offers a protective role against aSAH overall. As such 
we will collect data on aspirin use immediately before and during our study as well as 
include it in our data analysis given the potentially large potential for confounding. 
 
2.7 - Review of Relevant Methodology 
 The following section reviews methodologies relevant to our proposed study. A 
more detailed discussion of our study’s methods is found in Chapter 3. 
 
2.7.1 - Study Design 
 Our proposed study is designed as a prospective cohort study to examine the 
effects of MMP-9 levels in peripheral plasma samples on IA disease progression over a 
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follow up period. The choice to design our study as a prospective cohort stemmed from 
the lack of such studies with our exposure and outcome of interest in human subjects. 
Preceding studies completed on the topic have been prospective cohort designs with 
our outcome of interest but without assessment of our exposure of interest,27, 29 
retrospective cohort studies,24, 33, 48, 49, 50, 51 again without assessment of our exposure, 
case-control studies using a limited definition of IA progression,16, 19 or small scale 
randomized control trials performed using non-human subjects.5, 6, 7, 9,10, 52, 60, 62 This lack 
of studies of the prospective cohort design using our outcome definition limits our ability 
to assess the prognostic value of MMP-9 measurements via literature review alone. 
This study will thus be the first prospective cohort study to our knowledge with our 
outcome of interest related to MMP-9 levels. While we recognize that randomized 
control studies are the gold-standard of study design, it would be impossible to 
randomize our exposure of interest as this exposure is an intrinsic property unique to 
each subject’s physiology. Additionally, randomized administration of exogenous MMP-
9 would be highly unethical as a breach of the beneficence principle. Further, a 
retrospective study design would likely be underpowered as MMP levels are generally 
not included in previous studies. 
 
2.7.2. - Sampling of Study Population 
The population we are interested in is composed of subjects with previously 
identified IAs that have been conservatively managed. Identification of the sample 
population will be made via searching the Yale New Haven Health system patient 
databases for subjects recently diagnosed with an UIA as we are interested in IA 
progression rather than IA development or genesis. Sampling of the population will then 
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occur via consecutive sampling, with each subject contacted and recruited from most 
recently imaged IA to most distantly imaged IA until our requisite sample size is met. 
This is in contrast with other studies on the subject, largely because these previous 
studies did not include reimaging of IAs as part of their outcome assessment or due to 
their retrospective study design. Despite this lack of precedence, we feel as though this 
method of population sampling is the most cost-effective manner to assess for IA 
progression as it limits the number of resources required to obtain baseline imaging as 
well as the amount of time variation between baseline imaging and outcome imaging. 
Previous prospective cohorts on the topic enrolled subjects as they were diagnosed with 
IA, largely via incidentally identifying IAs. This approach to enrollment is highly time 
consuming, with one study taking 4 years to recruit 448 subjects.27 One Japanese study 
prospectively recruited a large number of subjects over a shorter period, however this 
was likely only possible due to aggressive IA screening protocols common in Japan29 
As such we feel as though this sampling method minimizes time and economic costs 
required for sampling to take place, as well as sampling bias while still maximizing the 
validity or fidelity of the data being gathered, while working within the framework of 
established domestic guidelines. Despite this, sampling bias may still be introduced by 
this method as it favors a sample with smaller, and thus perhaps more stable IAs as 
intervention decisions, while ultimately up to the patient, is advocated for larger IAs. As 
such, our study will attempt to draw conclusions about IAs from a sample that may be 
intrinsically more stable as less stable lesions will be treated and consequently excluded 




2.7.3 - Inclusion and Exclusion Criteria 
 The inclusion and exclusion criteria of our proposed study have been designed to 
be consistent with those of the majority of previous studies and reviews mentioned in 
chapter 1.53, 54 Generally these aim to exclude subjects who likely do not have MMP 
driven pathogenesis of their IAs such as those with connective tissue disorders, 
subjects with inherited disorders or malformations known to increase risk of IA, as well 
as those that cannot complete the process needed for outcome measurements, or 
those with surgically treated IAs. A further discussion of our study’s inclusion and 
exclusion criteria can be found in Chapter 3. 
 
2.7.4 - Exposure Determination 
 
Our primary exposure will be plasma levels of MMP-9 collected from the 
peripheral venous vasculature and assessed by the ELISA method. This method of 
measurement was chosen because of its use in prior studies, ease of acquisition, and 
minimal associated risks as our study is interested primarily in developing a feasible 
prognostic biomarker for IA progression validated by traditional imaging methods.13, 16, 
38, 55, 56 Despite this, our literature review demonstrated that many studies preferred to 
assess the presence of a variety of MMPs in vascular walls themselves by other 
techniques such as tissue zymography largely due to subject populations undergoing 
surgical treatment of IAs or from non-human subject harvests.57, 58, 59, 60, 61, 62, 63, 64 
However, as discussed above, these studies necessitate surgical intervention in order 
to acquire tissue samples and thus cannot be included in our conservatively managed 
study population. Further, our literature review did not find studies which attempted to 
define normal or healthy concentrations of MMP-9. Indeed, sparingly few studies were 
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found which assessed MMP-9 concentrations in healthy controls.9, 16, 20, 21 Even with 
such control values, it is impossible to determine if these are normal or healthy 
concentrations, or how an unhealthy concentration should be defined given this lack of 
large-scale data. As such, our exposure determination will be defined from within our 
study population relative to itself as greater than or less than the 50th percentile 
concentration of MMP-9 within the sample population. 
 
2.7.5 - Outcome Definitions 
 
 The outcome of interest in this study is IA progression defined as either a 1mm or 
greater increase in IA size in any dimension as assessed by CTA or MRA, or 
development of SAH. As in previous decisions regarding study design, our definition of 
growth was chosen as it agrees with the majority of other studies on the topic and is the 
most easily verified.29, 31, 33, 65, 66, 67, 68 Despite this, a number of other growth definitions 
have been used including a 2mm or greater increase in any dimension or a 1.5X 
increase in diameter.22, 48, 67, 69, 70 Occasionally investigators will include “obvious 
change in shape” or the development of a bleb in the aneurysmal wall, however 
qualitative assessments of IA progression are to be avoided in our study as they are 
less easily verified and can require majority consensus of a panel of radiologist for 
outcome designation.51 We also chose to include the development of SAH in our 
outcome assessment as this is seen as the most important and obvious outcome 
related to our study. 
 An additional aspect of our study design is the inclusion of a single 
neuroradiologist used to make outcome measurements. While this may be seen as 
introducing the risk of information bias perhaps avoided by using a panel of radiologists 
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for outcome designations as previously mentioned, studies on the topic do not support 
the notion of high intra-observer variability when making these types of assessments 
Indeed, one study comparing intra and inter-observer differences in IA measurements 
noting an intraclass correlation coefficient (ICC) of 0.97 when measuring IA height and 
0.98 when measuring IA width using CTA (95% CI), when a value of 1 indicates perfect 
agreement.70 Similar results were found when using MRA in the same study. 
Interobserver ICC by comparison are only slightly worse at 0.96 and 0.98 via CTA for IA 
height and width respectively and 0.95 and 0.94 via MRA for height and width 
respectively. Our study thus chose to avoid unnecessary complications in outcome 
assessment made by multiple observers in favor of a single observer as the quality of 
data obtained by either method is equivocal. 
 Further, we chose to assess IA progression via either CTA or MRA as long as 
the outcome assessment is the same as the most recent imaging technique for the 
subject in question. Again, while this may appear to introduce information bias due to 
the difference in imaging modality between subjects, a review of the available literature 
does not support this notion. When comparing IA measurements made by 4 
independent radiologists using CTA and MRA against measurements made by invasive 
angiography, a combined average variance of +16.1% (p=0.03) for CTA and -15.9% 
(p=0.03) for MRA was found.72 Similar results have been reported by other 
investigators.73 Thus, while significant bias may be found in interchanging imaging 
modalities for any one subject and different modalities over or underestimate IA size, 
this bias will be significantly avoided by making outcome assessments in the same 
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modality as baseline measurements and our study is interested in change of IA size 
over time rather than total IA size. 
 
2.7.6 - Sample Size and Statistical Significance 
 Although the theoretical link exists between MMP-9 and IA progression, in 
addition to the number of studies mentioned above that support this relationship, we 
cannot deny the heterogeneity of conclusions on the topic that, while not suggesting a 
protective role of MMP-9 on IAs, may still exist. As such we have chosen to utilize a 
two-tailed calculation to be able to detect this relationship in either direction. We will 
follow an analysis based on an alpha of 0.05 and a beta of 0.20 as this most closely 
follows the statistical methods as outlined in the above literature review. Further, while 
IAs are relatively common in the population at large, most of these lesions are 
undiagnosed, forcing us to identify subjects retrospectively via patient databases to 
meet our need for a sample size of 282 subjects. Our complete sample size calculation 
can be found in Appendix C. 
 
2.8 - Conclusion 
 This review demonstrated that our exposure of interest has been an ongoing 
topic of exploration for greater than 20 years. While initial, low-quality studies suggested 
that MMP-9 concentration in blood samples would be a conceptual dead end, renewed 
interest in the topic seems promising as multiple animal studies have demonstrated 
interesting pathological findings related to the exposure as well as a small number of 
human studies with similarly intriguing results.  
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 This review also demonstrated the relative lack of prospective cohort studies with 
our outcome of interest as we defined it, despite several large-scale prospective cohort 
studies relating risk factors for IA rupture over time. Despite this, several studies have 
attempted to expand this limited definition of IA progression to include IA growth, though 
these have largely been of a retrospective design. As such, ours is the first study of its 
kind to assess for a more complete definition of IA progression as it relates to MMP-9 
exposure via a prospective study design. These retrospective studies, nonetheless, 
have highlighted many important risk factors and confounders for IA rupture and growth 
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CHAPTER 3 - STUDY METHODS 
 
3.1 - Study Design 
This prospective study will retrospectively identify subjects who have had at least 
one intracranial aneurysm identified for the first time via CTA or MRA within the last 3 
years to determine the association between plasma MMP-9 concentration in peripheral 
venous blood of subjects with UIA and IA disease progression over a one-year follow-up 
period. A consent form to participate in the study will be presented to each subject after 
identification from the Yale New Haven Health (YNHH) system patient database. The 
consent form will be reviewed with the patient and signed to enroll the subject in the 
study. Demographic and pertinent medical data will be extracted via chart review and an 
intake survey. A copy of our intake survey can be found as part of our information form 
in Appendix A. These subjects will next have plasma MMP-9 concentration measured 
once at the time of or soon after enrollment and then be prospectively followed for one 
year starting on the date of their blood draw at which time they will have a repeat 
imaging assessment of their intracranial vasculature to assess for aneurysmal growth. 
Choice of imaging modality upon follow up will be the same modality as was used in the 
subject’s most recent imaging study in order to avoid mismeasurements related to 
alternating modalities. As repeat imaging every 1-2 years is recommended by national 
guidelines, all subjects included in the study are expected to have recent imaging with 
which to compare our outcome imaging with. While this may introduce variation in the 
timeline between baseline and outcome imaging measurements, this variation will be 
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minimized as compared to previous studies as discussed above while still maximizing 
our study’s feasibility and internal validity. There are no interventions related to this 
study. 
 
3.2 - Study Population and Sampling 
This study's population of interest is limited to subjects found within the YNHH 
system with an intracranial aneurysm diagnosed within the last 3 years who have 
chosen an observational treatment course. Criteria for exclusion will include prior 
aneurysmal surgical treatment, prior history of subarachnoid hemorrhage, history of 
blood clotting disorders such as Von Willebrand's Disease, Hemophilia, Factor 5 Leiden, 
or concurrent anticoagulation therapy, an inability to tolerate IV contrast as defined as 
previous contrast induced nephropathy, a history of intravenous contrast induced 
anaphylaxis, or a history of renal insufficiency, conditions associated with unstable IAs 
such as Polycystic Kidney Disease, Marfan’s syndrome, type IV Ehlers-Danlos 
syndrome, neurofibromatosis type 1, alpha-1-antitrypsin deficiency, fibromuscular 
dysplasia, pheochromocytoma, Klinefelter's syndrome, and congenital malformations 
such as coarctation of the aorta, bicuspid aortic valve, and intracranial arteriovenous 
malformations as these patients generally follow a distinctly different treatment course, 
present at earlier ages, or have a different underlying pathology of their IAs.1  We will 
also be forced to exclude subjects who have had baseline imaging only via traditional 
angiography as we are not willing to repeat this method of outcome assessment 
because it carries additional risks associated with its invasive nature. We will not 
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exclude patients based on IA size or other indications for IA surgical treatment if the 
subject consents to accepting the risk of choosing conservative treatment. 
Sampling will take place via peripheral venous blood once at a Yale University 
affiliated site. Quantification of plasma MMP-9 levels will be made via Enzyme-linked 
immunosorbent assay (ELISA).2 Follow up imaging will take place one year after this 
blood sample is collected and compared to the most recent aneurysm image taken prior 
to the start of the study period. All aneurysm measurements will be made by a single 
neuroradiologist blinded to subject identifiers and exposure status. The use of a single 
neuroradiologist may introduce an element of bias unique to this single observer, 
however this intra-observer variation has been found to be minimal by previous studies 
discussed above. Further, the use of a single observer will avoid inter-observer 
differences in measurements and evaluation.  
The population under study is composed of subjects with IAs demonstrated via 
MRA or CTA who have elected for a nonoperative treatment course. Blood sampling will 
occur soon after enrollment. Repeat imaging will occur one year after blood collection. 
Subjects will be split into exposure or non-exposure (control) groups based on the 
presence or lack of increased MMP levels as defined by being above or below the 50th 
percentile of MMP blood concentration within the study group. 
 
TABLE 1: Eligibility Criteria  
 
Inclusion Criteria Exclusion Criteria 
IA diagnosed < 3 years prior Aneurysmal hereditary syndromes 
Elected for conservative treatment Prior IA surgical treatment 
Age greater than 18 Bleeding disorders 
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Most recent IA imaging by CTA or MRA Current anticoagulation therapy 
 Cardiovascular congenital malformations 
 Prior aSAH 
 Inability to tolerate IV contrast 
 
3.3 - Recruitment 
Recruitment will be made via phone and email contact with eligible subjects 
found by using YNHH patient databases. We plan to recruit subjects with at least one IA 
identified within the last 3 years who have elected for conservative management. 
Retrospectively identifying subjects will minimize recruitment time. Each site will be 
assigned a research assistant who will provide information about the study to subjects 
and clinicians, enroll eligible patients, perform intake assessments, and obtain informed 
consent. 
 
3.4 - Subject Protection and Confidentiality 
 We will obtain Yale University’s Institutional Review Board approval prior to 
recruitment of subjects. Study personnel will access all participant electronic medical 
records (EMRs) on university-approved, encrypted, and secure electronic devices after 
completion of Health Insurance Portability and Accountability Act (HIPAA) training and 
Yale Human Subjects Protection training. Protected health information (PHI) not in 
electronic form will be stored within a locked cabinet in the locked office of the principal 
investigator to which only direct research staff will have access. All PHI will be disposed 
of in a secure manner after the study is completed. 
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 Participants will be required to grant written, informed consent in order to 
participate in the study. An example of the informed consent form can be found in the 
Appendix B. Study personnel will explain the consent form in a simple manner to allow 
participants to have the opportunity to ask questions and discuss concerns prior to 
consenting. The consent form contains a study description, duration of participation, and 
potential risks and benefits of the study in a style that is intelligible to a 6th grade 
reading level. It will be available in English with translation to other languages if needed. 
Interpreter services will be utilized as needed for other languages. For those who are 
unable to read, informed consent will be obtained after an oral presentation with a third-
party present to ensure all information is accurately represented.  
 
3.5 - Study Variables and Measures 
3.5.1 - Independent Variable 
The independent variable or exposure of this study will be MMP-9 levels 
measuring greater than the 50th percentile among study participants with an equal 
number of participants in each group. This measurement will be taken once starting at 
the onset of the study period. MMP-9 exposure status is measured once as they are 
assumed to be present on a chronic basis. Samples will be collected from the peripheral 
venous system at or below the level of the subject's antecubital fossa into a 4.5mL tube 
with ethylenediaminetetraacetic acid (EDTA) each month. The plasma will be separated 
from the total blood and stored frozen at -80 degrees C until analysis. Samples will then 
be sent to a participating laboratory where plasma MMP-9 levels will be measured using 




3.5.2 - Primary Dependent Variable: 
 The primary dependent variable is IA disease progression as defined as IA 
growth greater than 1mm in any dimension or development of aSAH during the follow-
up period. This definition agrees with previous studies discussed above in an attempt to 
establish outcome homogeneity. We will not include the formation of a bleb or change in 
IA shape in our outcome definition as this represents a subjective determination that will 
likely result in an increase in IA size and is thus better evaluated by this objective 
measurement. Determination of this growth will be made by a single, blinded 
neuroradiologist. Determination of IA rupture will be made by the attending radiologist at 
the presenting institution if a diagnosis of aSAH is made. 
 
3.5.3 - Confounding Variables 
Known confounders or secondary variables that contribute to aneurysmal growth 
as identified in the above literature review such as age, baseline aneurysmal size, 
female sex, hypertension status, smoking history, medications, family history, previous 
aSAH will be collected at intake through a combination of intake survey, radiological 
assessment of baseline images, and chart review. A summary of these variables and 
how we plan to test them can be found in Table 2. 
 
3.6 - Methodology Considerations 
3.6.1 - Blinding of Exposure 
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 Subjects will not be informed of their exposure status until after the study is 
completed, as it is unclear if exposure carries any risk. Exposure status will also not be 
released to any clinical teams as this may unnecessarily influence treatment decisions. 
Exposure status will be blinded from the neuroradiologist assessing our outcome by 
assigning subjects a randomly generated numerical code and removing any potential 
identifiers or exposure status information. 
 
3.6.2 - Blinding of Outcome  
Information related to disease progression assessed as our outcome upon study 
completion will be considered medically necessary information and will likely influence 
treatment decisions. As such, subjects will be offered the option to obtain the results of 
their imaging at the time of their outcome assessment in which to share with their 
treatment teams in order to facilitate proper treatment decisions. In this way, there will 
be no blinding of outcomes related to this study. This is not seen as a threat to the 
validity of the study as the study is considered complete upon outcome image 
acquisition.  
 
3.6.3 - Assignment of Intervention  
Subjects will be assigned to exposure or non-exposure groups based on average 
MMP-9 level. The unexposed group is defined as those subjects whose MMP-9 level is 
below the 50th percentile of the total cohort. While this method of exposure assignment 
may be seen as introducing a form of sampling and information bias as it is unknown 
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how MMP-9 levels will be distributed within the sample, no normal or healthy level of 
MMP-9 concentration can be found in the literature to which compare to. 
 
3.6.4 - Adherence 
 It is believed that recruited subjects will be highly motivated to remain in the 
study due to the severe nature of their condition and the established need for periodic 
monitoring. However, it is critical to the study that subjects attend their appointments for 
blood sampling and reimaging. As such, patients will be reminded of their appointment 
one week in advance to the date of their appointments. However, if the initial 
appointment is missed, the subject will be contacted via phone and scheduled for blood 
draw at their earliest convenience but not to exceed one month after their missed 
appointment in order to minimize deviations from our proposed study timeline. If the 
follow up appointment is missed the subject will be contacted by phone and email to 
schedule outcome imaging up to one week after their missed appointment in order to 
minimize variations in outcome assessment timelines. If a subject is unable to 
reschedule appointments in this time frame they will be dropped from the study. We 
recognize this may introduce a degree of compliance bias. However, we expect 
adherence to be extremely high as a result of our study design, namely that we have 
defined our outcome of interest to include those subjects who experience an IA rupture 
who would otherwise not be able to be assessed for IA growth.  
  
3.6.5 - Monitoring of Adverse Events  
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It is possible that subjects experience aSAH or symptoms warranting 
reevaluation of their IA during the study period. If this should occur the subject should 
call 911 to get evaluated as soon as possible and follow all recommendations of his or 
her care team. This will likely include urgent neurovascular imaging via CT scan to 
assess for aSAH. If repeat imaging shows aSAH or marked increase in IA size 
warranting surgical intervention, then the subject will be included in the study as the 
outcome of interest has been demonstrated, with no other intervention required from the 
study administrators. These patients should undergo whichever procedure is 
recommended by their care team. If imaging occurs during the follow-up period that 
does not demonstrate IA progression, but the subject undergoes IA surgical or 
endovascular treatment, then the subject will be dropped from the study in agreement 
with previous study protocols as above. If repeat imaging occurs during the follow up 
period that does not show IA progression and the subject does not undergo IA 
intervention, the subject will still be included in the study if they can undergo repeat 
imaging at the end of the follow up period.  
 
3.6.6 - Data Collection 
Subjects will fill out an intake survey to assess patient demographics such as 
age, sex, height, weight, smoking history, hypertension status, family history, allergies, 
medications, and presence of IA symptoms, among other parameters. A complete 
example of the intake survey can be found in Appendix A. The electronic medical record 
will be referenced to gather aneurysmal specific characteristics such as size, location, 
most recent imaging, most recent imaging modality. MMP-9 levels will be collected once 
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starting as soon as possible after consenting. Outcome data via imaging will be 
collected one year after the last exposure measurement is collected by a single 
neuroradiologist blinded to subject identifiers and exposure status. While a single 
observer introduces a potential for intra-observer information bias, multiple observers 
have the risk of introducing their own inter-observer information bias. Further, data 
suggests that this intra-observer bias is generally minimized as described in Chapter 2. 
 
3.6.7 - Sample Size Calculation  
 The proposed sample size is 282 subjects calculated using Power and Precision 
4 Software and the UCSF Sample Size Calculator.3, 4 Several assumptions were 
required to arrive at this sample size. It was assumed that all subjects with intracranial 
aneurysms could be placed into two groups, either the elevated MMP-9 group (MMP+), 
or the non-elevated MMP-9 group (MMP-). Further it was assumed that growth rates will 
be increased in the MMP+ group as compared to the MMP- group, although this 
parameter was not specifically measured in previous studies assessing growth risk. 
Thus, any study describing the proportion of subjects with growing IAs by a variety of 
variables contains a mixture of MMP+ and MMP- subjects, where MMP+ subjects 
contribute to the proportion of growing IAs at a higher rate, and MMP- subjects, while 
still contributing to the proportion of growing IAs depending on their co-variables for 
growth, grow slower or less frequently and thus decrease the proportion of growing IAs 
as a whole.5 ,6 The conclusion of these studies thus acts as an average proportion of 
growing IAs in subjects with elevated and non-elevated MMP levels. Our estimated 
effect size is then found by assuming that the proportion of growing IAs in the 
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unmeasured MMP+ subjects of previous studies will be 5% higher than the total number 
of growing IAs growing due to other risk factors for growth, while the MMP- group will be 
5% lower than the total but still grow according to their own non-MMP risk factors for 
growth, for an effect size of 10%. The proportion of aneurysms growing in one year was 
assumed to be 9% based on work by Villablanca demonstrating that 18% of aneurysms 
grew over a period of 2.2 years.6 Thus, we assume that 4% of MMP- subjects will 
progress and 14% of MMP+ subjects will progress over one year. Setting the power of 
our proposed statistical analysis at 80% for a two-sided hypothesis, with a confidence 
interval of 95%, with the above described effect size of 10% allows us to arrive at the 
sample size of 256 subjects. The additional 26 subjects proposed are to account for an 
estimated 10% loss to follow up over the one-year study period. Since mortality is an 
expected complication associated with our outcome of interest of disease progression, 
subject mortality will not affect our study population size and thus need not be factored 
into our sample size calculation. 
 
3.6.8 - Statistical Analysis 
The characteristics of our sample population will be analyzed by univariate 
analysis to assess for common factors influencing IA progression as summarized in 
Table 2. Bivariate analysis will be conducted using the Chi-squared test of significance 
to assess for aneurysm progression, defined dichotomously as either present or not 
present, in the setting of MMP-9 levels with a two tailed test for significance set as 
p<0.05. Final models will be adjusted for known confounders, identified as categorical 
variables, reaching a significance level of p<0.05 using multiple logistic regression to 
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assess if these confounders share an association with our exposure of interest as 
established by preceding studies mentioned above. While a potential for selection and 
information bias exists in defining exposure status according to percentiles defined 
within the study group, normal or healthy levels of MMP-9 have not been established in 
the population at large, making it difficult to define high or low levels in other ways. 
Sensitivity analysis will be completed on our sample’s MMP-9 level distribution to 
identify an alternative exposure cutoff associated with IA progression. 
 
Table 2: Subject and IA Characteristics with Statistical Tests 
Subject 
Characteristics 
MMP - Group MMP+ Group p-value 
Age mean ± SD mean ± SD ANOVA 
Sex at Birth n (%) n (%) Chi-square 
Pack Years mean ± SD mean ± SD ANOVA 
Hypertension n (%) n (%) Chi-square 
Japanese Ancestry n (%) n (%) Chi-square 
Finish Ancestry  n (%) n (%) Chi-square 
Doxycycline Use n (%) n (%) Chi-square 
Aspirin Use n (%) n (%) Chi-square 
Statin Use n (%) n (%) Chi-square 
IA Characteristics    
IA Size (most 
recent) 
mean ± SD mean ± SD ANOVA 
MCA IA Location n (%) n (%) Chi-square 
Posterior IA 
Location 
n (%) n (%) Chi-square 
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Anterior IA Location n (%) n (%) Chi-square 
IA Multiplicity n (%) n (%) Chi-square 
Previous IA Growth n (%) n (%) Chi-square 
 
 
3.7 - Timeline and Resources 
 Pending Institutional Review Board (IRB) approval, we will retrospectively identify 
and recruit subjects with an UIA first diagnosed within the last 3 years over a period of 6 
months. During recruitment, peripheral blood sampling of subjects to determine 
exposure status will begin. Repeat imaging will occur one year after blood sample 
collection, allowing the study to be completed within 18 months. After this we will 
interpret the results and report our findings. 
 Study personnel will include one principal investigator, Dr. Kevin Sheth, one co-
principal investigator, Peter Stampfel, to coordinate blood sample collection and 
analysis, intake survey administration, electronic medical record data collection, and 
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Chapter 4 - Conclusion 
4.1 - Advantages 
Our study has several strengths including the use of a prospective design, 
expanded definition of IA progression, an exceptional ethical profile, and an efficient 
subject recruitment 
We propose a prospective cohort with repeat imaging obtained over shorter 
periods relative to previous studies. This will allow us to compare our exposure to a gold 
standard of disease monitoring in a way uncommonly employed in previous studies. Our 
study’s prospective design also allows us to include a more comprehensive definition of 
IA progression. As other studies have avoided acquiring repeat imaging and thus were 
only able to define IA progression as IA rupture, they failed to acquire data on IA growth 
and thus the risk of IA rupture in UIAs. Our prospective design with repeat imaging on 
outcome assessments allows us to include RIAs and growing but currently UIAs within 
our definition of disease progression. 
 Additionally, our study design is exceptionally ethical as it fits within the 
recommended IA monitoring guidelines established by the AHA. As such it does not 
require significant deviation from standard of care. Further, the only deviation from 
standard of care is a peripheral venous blood draw and does not represent any 
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meaningful risk to the subjects. The only subjects included are those who have chosen 
conservative treatment. This minimal deviation from standard of care also suggests that 
our study design has maximized its feasibility while still acquiring high quality data. IA 
imaging is time consuming and expensive, leading many previous studies to avoid a 
prospective design, instead opting for retrospectively collected data. However, this has 
necessarily led to lower quality data as follow up imaging has been acquired on a highly 
variable timeline.  
Retrospectively identifying subjects with IAs to be included in our prospective 
cohort also reduces the amount of time that would be needed to recruit subjects as they 
are identified upon presentation as is done in traditional prospective cohort studies. 
Further, using recently acquired images that are independently evaluated by our blinded 
neuroradiologist reduces the time and cost of acquiring our own intake/baseline 
imaging. 
 
4.2 - Disadvantages 
 Despite these advantages as well as our significant efforts to optimize our study 
design, we acknowledge that this study has several shortcomings. Perhaps the main 
shortcoming of this study is that it measures a single MMP. While we have attempted to 
choose the MMP with the strongest evidence for its contribution to IA disease, it is likely 
that it is only one of many enzymes contributing to the formation and progression of IA 
lesions. Thus, future studies may find it fruitful to expand their IA markers to include the 
enzymes, second messengers, and inflammatory cells likely to be found implicated in IA 
progression upon a broader search of the scientific literature. Additionally, several 
studies have demonstrated the importance of endogenous inhibitors of MMPs. Further 
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studies on the topic may find it worthwhile to include TIMP levels and MMP/TIMP ratios 
into their exposure determination.  
While it is well established that MMPs as a family of enzymes play an important 
role in the formation and progression of aneurysms, some authors have suggested that 
aneurysm growth is episodic.1, 2 This study will then only succeed in taking a snapshot 
in time via its short assessment period for MMP-9 exposure. This will likely lead to 
under or overestimating exposure levels and outcomes. As such, the short period of 
exposure evaluation proposed in this study likely represents a narrow time window 
which increases the chance that any one subject will be misplaced in the wrong 
exposure group. Ideally, MMP-9 levels will be drawn as regularly as possible to avoid 
this misclassification of exposure, however it is unlikely that subjects will be willing to 
adhere to such numerous blood collections. Our study attempted to maximize its 
feasibility at the expense of absolute validity. 
Lastly, there was a lack of reliable information related to the calculation of our 
effect size. This required us to make several assumptions that, while not wholly 




4.3 - Health Significance 
Intracranial aneurysms are incredibly common, extremely dangerous, and difficult 
to monitor via traditional means of MRA or CTA. Further, our collective understanding of 
the pathological processes at work is still in development. These factors, when 
combined, leave many patients with this condition at significant risk for deadly or 
62 
 
debilitating consequences. The development of an easily acquired alternative to disease 
progression as proposed in this study would be invaluable to many individuals harboring 
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Appendix A: Subject Information Form 
 
 
Section I: To be completed by Subject  
 
Name:_______________  Sex at Birth:_________   DOB:_____________ Age:______ 
         (dd/mm/yy) 
Phone Number:________ Email:__________      
May we leave a voice message for you? Yes____ No____ 
Address:_____________________________________ 
City:__________________      State:____________   Postage Code:_______________ 
Have you ever been diagnosed with high blood pressure? Yes____ No____ 
Have you ever been diagnosed with kidney dysfunction? Yes____ No____ 
Do you use tobacco? Yes____ No____   If yes, how much per day? ________ 
Are you of Japanese ancestry? Yes____ No____ 
Are you of Finish ancestry? Yes____ No____ 
Have you ever had a reaction to intravenous or IV contrast? Yes____ No____ 
Do you or any members of your family have any of the following conditions: 
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Polycystic Kidney Disease: Yes____ No____   Marfan Syndrome: Yes____ No____ 
Ehlers-Danlos Syndrome: Yes____ No____  Klinefelter's syndrome: Yes____ No____ 
Neurofibromatosis type 1: Yes____ No____  
Alpha-1-antitrypsin deficiency: Yes____ No____ 
Fibromuscular dysplasia: Yes____ No____  Pheochromocytoma: Yes____ No____ 
Have you ever been diagnosed with coarctation of the aorta OR bicuspid aortic valve 
OR intracranial arteriovenous malformations? Yes____ No____ 
Have you ever been diagnosed with a bleeding disorder?: Yes____ No____ 
Have you ever been diagnosed with a blood clotting disorder?: Yes____ No____ 
If yes, what is the bleeding OR blood clotting disorder named?:  ___________________ 
Have you ever had brain OR aneurysm surgery? Yes____ No____  
If yes, when?:________ 
 
Section II: To be Completed ONLY by Research Staff upon Intake 
 
Subject MRN:________________       Subject Identification Code:_________________ 
Date of Blood Draw:________________    MMP-9 Level (ng/ml):__________________ 
        (dd/mm/yy) 
Heart Rate:_______ Blood Pressure:____/____  Respirations:______ O2 Sat:________ 
Height (cm):_____________    Weight (Kg):______________ 
 
Medication Dose Frequency 
   
   
   
   












Date of most recent cerebral vascular imaging:_____________ 
Imaging type: CTA:___  MRA:___ Number of IAs:_______   
IA symptoms present?:Yes__  No__ 
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________ 
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________ 
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________ 
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________ 
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________ 
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________ 
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________ 
 
Section III: To be Completed ONLY by Research Staff upon Study Completion 
Heart Rate:________ Blood Pressure:____/____  Respirations:______ O2 Sat:_______ 
Height (cm):__________    Weight (Kg):___________  IA symptoms?:Yes____  No____ 
Incidence of SAH during study period? Yes____  No____ 
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Incidence of subject death during study period? Yes____ No____   
If yes, when________   Cause of death:________ 
Imaging type: CTA:___  MRA:___    Date of Imaging:_____________ 
        (dd/mm/yy) 
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________ 
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________ 
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________ 
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________ 
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________ 
IA Identification Number:_______ IA H x L x W(mm):___x___x___ IA location:________ 






































Appendix B: Informed Consent Form 
 
Informed Consent form for adults participating in the study titled “The Effect of 
Plasma Levels of Matrix Metalloproteinase-9 on Intracranial Aneurysm 
Progression” 
 
Title of Study: The Effect of Plasma Levels of Matrix Metalloproteinase-9 on 
Intracranial Aneurysm Progression 
Principal Investigator: Kevin Sheth, MD 
Co-Principal Investigator: Peter Stampfel 
Affiliation: Yale University School of Medicine and Yale New Haven Health System 
 
This Informed Consent Form has two parts: 
● Information Sheet (to share information about the research with you) 
● Certificate of Consent (for signatures if you agree to take part) 
 
You will be given a copy of the full Informed Consent Form 
 
 
PART I: Information Sheet 
 
Introduction 
 I am Peter Stampfel, a Physician Associate student at the Yale School of 
Medicine. My team and I are doing research on a disease called intracranial aneurysms 
which can cause bleeding inside a person’s brain. We are inviting you to participate in 
our research because you have been found to have this disease but have decided with 
your doctor to not have surgery. We are planning to invite nearly 300 people like you to 
study this bleeding disease. 
 Please read this form to help you decide if you would like to participate in our 
study. You do not have to decide today, so please take your time. There may be some 
medical words or concepts that are foreign to you so please let us know if you have any 
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confusion or would like to ask any questions either now or later. You are allowed to talk 
about this study with anyone you choose to help you decide. 
 
Purpose of the research 
 Intracranial aneurysms are a common problem in the blood vessels of the brain. 
Sometimes these aneurysms rupture, much like a balloon, causing bleeding inside of 
the head. The problem we have is that only some of these balloons pop, and we are not 
very good at knowing when or why they do so. Taking pictures of the brain can help us 
know when they may pop, but we are hoping to learn about a blood test that will also 
help us know. This research is going to help us see if our blood test will help us keep 
people with the disease from having this brain bleeding. 
 
Type of Research Intervention 
 This research will involve asking you a few questions, doing a brief physical 
exam, and taking a small amount of your blood from your arm once and testing it in a 
laboratory. One year later we will take a picture of your brain to see how your aneurysm 
is doing as well as ask you questions to see if anything has changed for you. Your 
doctor may have told you that taking pictures of your brain over time is a normal part of 
how they would take care of you anyway. This study will only add a few extra questions 
and a blood test to the normal way we take care of aneurysms. 
 
Participant selection 
We are inviting all adults with an intracranial aneurysm that has been found 
within the past 3 years in the Yale New Haven Health care system and who have not 
had surgery to fix it to participate in our study. You have been invited because you have 
at least one intracranial aneurysm that was found in the last three years and have 




 Your participation in this study is completely voluntary. We cannot and are not 
forcing you to participate, it is your choice. You are allowed to change your mind and 
stop participating later even if you have already agreed. Whether you chose to 
participate or not will not affect your normal care with your normal doctor. If you choose 
to participate, you will still be offered the normal treatment for intracranial aneurysms 
that is routinely offered in the Yale New Haven Health system. We will tell you more 
about this treatment later. 
 
A. Procedures and Protocol 
 You will receive the normal treatment for your condition according to the 
decisions that you and your doctor make. Often these are made by following national or 
institutional recommendations. Treatment is either to have surgery to fix the aneurysm 
or to watch and wait to see if it gets worse before having surgery. Often aneurysms will 
not get so bad as to need surgery, but sometimes they do. This means that if your 
aneurysm starts to cause you new problems, such as headaches or vision changes, you 
will likely receive a picture of your brain. If the picture shows that the aneurysm may 
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begin bleeding, you will be offered the option to have surgery to fix it. If the picture does 
not show any of the bad warning signs, you will not get surgery, but your other problems 
will still be treated normally. Sometimes an aneurysm begins to bleed without warning. 
These can be deadly, and all efforts will be made to help make sure you are alright. 
 An important part of our research is a small blood test. We will take blood from 
your arm using a needle and place it in a test tube. We will have to do this once. We will 
take about two spoonsful of blood for our tests. If there is any leftover blood at the end 
of our research we will destroy it and not let anyone else use it. 
 
B. Description of the Process 
- You will make two visits to the clinic during the research 
- A small amount of blood will be taken from your arm during the first visit. This 
blood will be sent to a laboratory to see how much of a particular substance is in 
it normally. We will also ask you a few questions about how your health is and 
take a few measurements such as your blood pressure and your weight.  
- One year later we will take a picture of your brain in the same way your doctor 
has been doing. Then we will compare the new picture to your old pictures to see 
if anything has changed. We will also ask you some questions and repeat 




 This research takes place over 18 months or one and a half years. The first 6 
months will be spent recruiting subjects like yourself to join our study. After this, you will 
be asked to come to the clinic a total of 2 times. The first visit will include a blood 
collection and a physical exam. Then a year later we will take a picture of your brain. At 
the end of that time our research will be finished. 
 
Side Effects 
You may have a few side effects during the study. We will need to use a needle 
to get your blood to test and the pinch from the needle can be uncomfortable. Some 
people are very afraid of needles and sometimes can pass out. The needle can 
sometimes cause bleeding in your arm that may hurt, or rarely cause an infection. To 
help avoid an infection we will always use a new needle and clean your skin. Some 
people are allergic to our skin cleaner and may have a reaction. If this is the case we 
will use a different cleaner. We will do everything we can to make sure this does not 
happen and will watch you closely to keep track of any bad effects. If any of these side 
effects occur we will discuss it together with you to help decide if certain medications 
can help fix the problem. 
 
Risks 
 There is the risk that your aneurysm will get worse during the study. If this 
happens your doctor will be told, and you and your loved ones will be able to talk with 
them to help you decide what to do. This study will not keep you from getting any 
treatment you may need. Also, while we will make every effort to protect your personal 





 Your participation in our study will help us gain knowledge about aneurysms. In 
the future, this information can be used to help people with this disease, to keep them 
from bleeding, and to help doctors know when they should have surgery. Because 
intracranial aneurysms are common throughout the world, your participation may help 
save lives in the future. Many aneurysms also run in families and your participation may 
even help one of your loved ones. 
 
Reimbursements 
 There will be no costs to you for participation in the study. Your blood tests and 
imaging will be paid for by our funding. There are no reimbursements for participation. 
  
Confidentiality 
 The information that we collect from this research project will be kept confidential 
and only disclosed if required by the law. Information about you that will be collected 
during the research will be put away and no-one but the researchers and the research 
supervisors at Yale University institutions. These people are also required to keep all your 
information confidential. Any information about you will have a number on it instead of 
your name. Only the researchers will know what your number is, and that information will 
be locked away. None of your personal information will be included without your 
permission when the research is published. 
 We will help protect your information by only accessing it on university approved 
and secured electronic devices. Any physical papers that we collect will be locked in a 
cabinet in my locked office. 
 
Sharing the Results 
 The knowledge that we get from this study will be shared with you after the study 
is complete and before the results are published. If we have any reason to think that you 
are at any increased risk of brain bleeding we will tell you immediately. 
 
Right to Refuse or Withdraw 
 It is your choice to participate in this study. It is also your choice to change your 
mind if you wish to not complete the study at any time. If you choose to not complete the 
study you will not be allowed to rejoin again. 
 
Alternatives to Participating 
 If you do not want to take part in this study you will be provided with the care that 
you have agreed upon with your doctor. 
 
Who to Contact 
 If you have any questions you may ask them now or later. If you wish to ask 
questions later you may contact the Principal Investigator at his office: Peter Stampfel, 




If you have any questions about your privacy rights, please contact the Yale Privacy 
Officer at 444-444-4444. 
 
This proposal has been reviewed and approved by the Yale Institutional Review Board, 
which is a committee whose task it is to make sure that research participants are 
protected from harm. If you have any complaints about this research or questions about 
your rights as a participant, please contact the Yale Institutional Review Boards at 333-
333-3333 or email hrpp@yale.edu. 
 
 
PART II: Certificate of Consent 
 I have read, or someone has read to me, the information in this document. I have 
had the opportunity to ask questions about it and any questions that I have asked have 
been answered to my satisfaction. By signing this form, I consent voluntarily to 
participate as a participant in this research. By refusing to sign I understand that I will 
not be able to participate in this research in the future. My signature also indicates that I 
have received a copy of this document. 
 
Print Name of Participant__________________      
Signature of Participant ___________________ 
Date ___________________________ 
 Day/month/year    




I have witnessed the accurate reading of the consent form to the potential participant, 
and the individual has had the opportunity to ask questions. I confirm that the individual 
has given consent freely.  
 
Print name of witness_____________________             AND         Thumb print of 
participant 
Signature of witness ______________________ 
Date ________________________ 




Statement by the researcher/person taking consent 
I have accurately read out the information sheet to the potential participant, and to 
the best of my ability made sure that the participant understands that the following will 
be done: 
1. Health Information will be gathered 





3. Repeat imaging will be completed at a later date 
4. Their information will be protected in accordance with standard practice 
5. They can withdraw from the study at any point and are choosing to participate by 
their own choosing 
I confirm that the participant was given an opportunity to ask questions about the 
study, and all the questions asked by the participant have been answered correctly and 
to the best of my ability. I confirm that the individual has not been coerced into giving 
consent, and the consent has been given freely and voluntarily.  
   
 A copy of this ICF has been provided to the participant. 
 
Print Name of Researcher/person taking the consent________________________ 
    
Signature of Researcher /person taking the consent__________________________ 
Date ___________________________    






































Appendix C: Sample Size Calculation 
 
Our Sample size was based on a calculation program assuming a normal 
distribution for MMP levels and a two tailed hypothesis. This program was cross 
referenced using the UCSF Sample Size calculator to compare dichotomous outcomes 
using the Chi-square statistic. Our calculated sample size of 256 subjects was 
expanded by 10% (26 subjects) to a total of 282 subjects to account for expected loss to 
follow up. Specific parameters of the calculation are listed below: 
 
Alpha = 0.05 
Beta = 0.20 
Power = 0.80 
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